Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Boehringer Ingelheim
Queensland Health
Cipla
Argus Health
McKinsey
Federal Trade Commission
Express Scripts
AstraZeneca
UBS

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,378,508

« Back to Dashboard

Which drugs does patent 7,378,508 protect, and when does it expire?

Patent 7,378,508 protects DIFICID and is included in one NDA.

This patent has ninety-three patent family members in twenty-five countries.
Summary for Patent: 7,378,508
Title:Polymorphic crystalline forms of tiacumicin B
Abstract: The invention relates to novel forms of compounds displaying broad spectrum antibiotic activity, especially crystalline polymorphic forms and amorphous forms of such compounds, compositions comprising such crystalline polymorphic forms and amorphous forms of such compounds, processes for manufacture and use thereof. The compounds and compositions of the invention are useful in the pharmaceutical industry, for example, in the treatment or prevention of diseases or disorders associated with the use of antibiotics, chemotherapies, or antiviral therapies, including, but not limited to, colitis, for example, pseudo-membranous colitis; antibiotic associated diarrhea; and infections due to Clostridium difficile ("C. difficile"), Clostridium perfringens ("C. perfringens"), Staphylococcus species, for example, methicillin-resistant Staphylococcus, or Enterococcus including Vancomycin-resistant enterococci.
Inventor(s): Chiu; Yu-Hung (San Diego, CA), Che; Tessie Mary (San Diego, CA), Romero; Alex (San Diego, CA), Ichikawa; Yoshi (San Diego, CA), Shue; Youe-Kong (Carlsbad, CA)
Assignee: Optimer Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/831,886
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Composition;

Drugs Protected by US Patent 7,378,508

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Cubist Pharms Llc DIFICID fidaxomicin TABLET;ORAL 201699-001 May 27, 2011 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,378,508

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,507,564 Tiacumicin production ➤ Try a Free Trial
8,518,899 Macrocyclic polymorphs, compositions comprising such polymorphs and methods of use and manufacture thereof ➤ Try a Free Trial
8,586,551 18-membered macrocycles and analogs thereof ➤ Try a Free Trial
8,859,510 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof ➤ Try a Free Trial
8,883,986 Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof ➤ Try a Free Trial
8,728,796 Tiacumicin production ➤ Try a Free Trial
7,863,249 Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof ➤ Try a Free Trial
7,906,489 18-membered macrocycles and analogs thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,378,508

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I453015 ➤ Try a Free Trial
Taiwan 201350114 ➤ Try a Free Trial
Taiwan I425942 ➤ Try a Free Trial
Taiwan 200840562 ➤ Try a Free Trial
Taiwan I306097 ➤ Try a Free Trial
Taiwan 200626585 ➤ Try a Free Trial
Slovenia 2070530 ➤ Try a Free Trial
Slovenia 1539977 ➤ Try a Free Trial
Russian Federation 2478643 ➤ Try a Free Trial
Russian Federation 2009131727 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Teva
Johnson and Johnson
Baxter
Cerilliant
Fish and Richardson
Chubb
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot